http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
XI, 181 p. 57 illus., 39 illus. in color. online resource.
This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P – Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.